GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Cash-to-Debt

Sarepta Therapeutics (Sarepta Therapeutics) Cash-to-Debt

: 1.20 (As of Dec. 2023)
View and export this data going back to 1997. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sarepta Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.20.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sarepta Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Sarepta Therapeutics's Cash-to-Debt or its related term are showing as below:

SRPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.2   Med: 2.17   Max: 33.24
Current: 1.2

During the past 13 years, Sarepta Therapeutics's highest Cash to Debt Ratio was 33.24. The lowest was 1.20. And the median was 2.17.

SRPT's Cash-to-Debt is ranked worse than
74.72% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs SRPT: 1.20

Sarepta Therapeutics Cash-to-Debt Historical Data

The historical data trend for Sarepta Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 1.81 1.83 1.23 1.20

Sarepta Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 1.46 1.36 1.26 1.20

Competitive Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cash-to-Debt falls into.



Sarepta Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sarepta Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Sarepta Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sarepta Therapeutics  (NAS:SRPT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Sarepta Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Executives
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme officer: Senior Vice President, CFO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901